The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
ARUNLAKSHANA, O., & SCHILD, H. O. (1959) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1959.tb00928.x · Cited by 3,938
Molecular Dissection of Two Distinct Actions of Melatonin on the Suprachiasmatic Circadian Clock
Liu, C., Weaver, D. R., Jin, X., Shearman, L. P., Pieschl, R. L., Gribkoff, V. K., & Reppert, S. M. (1997) · Neuron · doi:10.1016/s0896-6273(00)80350-5 · Cited by 723
Effects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
Berg, K. A., Maayani, S., Goldfarb, J., Scaramellini, C., Leff, P., & Clarke, W. P. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.94 · Cited by 510
Evidence for norepinephrine-mediated collateral inhibition of locus coeruleus neurons
Aghajanian, G. K., Cedarbaum, J. M., & Wang, R. Y. (1977) · Brain Research · doi:10.1016/0006-8993(77)90083-x · Cited by 489
Catecholamine regulation of the prefrontal cortex
Arnsten, A. F. T. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100208 · Cited by 488
Souêtre, E., Salvati, E., Belugou, J.-L., Pringuey, D., Candito, M., Krebs, B., Ardisson, J.-L., & Darcourt, G. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90207-2 · Cited by 396
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Gobert, A., Rivet, J.-M., Lejeune, F., Newman-Tancredi, A., Adhumeau-Auclair, A., Nicolas, J.-P., Cistarelli, L., Melon, C., & Millan, M. J. (2000) · Synapse · doi:10.1002/(sici)1098-2396(20000601)36:3<205::aid-syn5>3.0.co;2-d · Cited by 336
Self-citation5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37669-4 · Cited by 334
Cited by
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
Circadian genes, rhythms and the biology of mood disorders
McClung, C. A. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.02.003 · Cited by 666
Circadian rhythm disturbances in depression
Germain, A., & Kupfer, D. J. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.964 · Cited by 644
“New antidepressants, such as agomelatine, which has both melatonergic and serotonergic receptor action profiles (Millan et al., 2003), can advance the circadian phase in both rats and humans (Kräuchi et al.”
BackgroundMT1 and MT2 Melatonin Receptors: A Therapeutic Perspective
Liu, J., Clough, S. J., Hutchinson, A. J., Adamah-Biassi, E. B., Popovska-Gorevski, M., & Dubocovich, M. L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124742 · Cited by 630
Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., & Olcese, J. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002832 · Cited by 621
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development
de Bodinat, C., Guardiola-Lemaitre, B., Mocaër, E., Renard, P., Muñoz, C., & Millan, M. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3140 · Cited by 593
Self-citationMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Self-citationHardeland, R., Madrid, J. A., Tan, D., & Reiter, R. J. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00934.x · Cited by 448
Update on melatonin receptors: IUPHAR Review 20
Jockers, R., Delagrange, P., Dubocovich, M. L., Markus, R. P., Renault, N., Tosini, G., Cecon, E., & Zlotos, D. P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13536 · Cited by 422
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Melatonin and its analogs in insomnia and depression
Cardinali, D. P., Srinivasan, V., Brzezinski, A., & Brown, G. M. (2012) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2011.00962.x · Cited by 353
Physiology and pharmacology of melatonin in relation to biological rhythms
Zawilska, J. B., Skene, D. J., & Arendt, J. (2009) · Pharmacological Reports · doi:10.1016/s1734-1140(09)70081-7 · Cited by 336
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Pandi-Perumal, S. R., BaHammam, A. S., Brown, G. M., Spence, D. W., Bharti, V. K., Kaur, C., Hardeland, R., & Cardinali, D. P. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9337-4 · Cited by 320
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis
Banasr, M., Soumier, A., Hery, M., Mocaër, E., & Daszuta, A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.025 · Cited by 318
Stimuli-responsive In situ gelling system for nose-to-brain drug delivery
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 298
A Review of Melatonin, Its Receptors and Drugs
Emet, M., Ozcan, H., Ozel, L., Yayla, M., Halici, Z., & Hacimuftuoglu, A. (2019) · The Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.0267 · Cited by 291
Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., Bonifacino, T., Mallei, A., Baldelli, P., Racagni, G., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008566 · Cited by 289
Millan, M. J. (2005) · Therapies · doi:10.2515/therapie:2005065 · Cited by 283
Self-citationMode of action of agomelatine: Synergy between melatonergic and 5-HT2Creceptors
Racagni, G., Riva, M. A., Molteni, R., Musazzi, L., Calabrese, F., Popoli, M., & Tardito, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.595823 · Cited by 282
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Self-citationKasper, S., Hajak, G., Wulff, K., Hoogendijk, W. J. G., Montejo, A. L., Smeraldi, E., Rybakowski, J. K., Quera-Salva, M.-A., Wirz-Justice, A. M., Picarel-Blanchot, F., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05347blu · Cited by 257
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Millan, M. J. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.038 · Cited by 255
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212
The circadian basis of mood disorders: Recent developments and treatment implications
Monteleone, P., & Maj, M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.007 · Cited by 185
Guardiola‐Lemaitre, B., De Bodinat, C., Delagrange, P., Millan, M. J., Munoz, C., & Mocaër, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12720 · Cited by 182
Self-citationNeurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction
Hardeland, R. (2012) · The Scientific World Journal · doi:10.1100/2012/640389 · Cited by 173
Leproult, R., Van Onderbergen, A., L’Hermite‐Balériaux, M., Van Cauter, E., & Copinschi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02341.x · Cited by 167
Jet lag, circadian rhythm sleep disturbances, and depression: the role of melatonin and its analogs
Srinivasan, V., Singh, J., Pandi-Perumal, S. R., Brown, G. M., Spence, D. W., & Cardinali, D. P. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0065-y · Cited by 129
Païzanis, E., Renoir, T., Lelievre, V., Saurini, F., Melfort, M., Gabriel, C., Barden, N., Mocaër, E., Hamon, M., & Lanfumey, L. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990514 · Cited by 123
Circadian Rhythms, Melatonin and Depression
A. Quera Salva, M., Hartley, S., Barbot, F., C. Alvarez, J., Lofaso, F., & Guilleminault, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796197188 · Cited by 100
Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients
Quera‐Salva, M., Lemoine, P., & Guilleminault, C. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1112 · Cited by 92
Boulle, F., Massart, R., Stragier, E., Païzanis, E., Zaidan, L., Marday, S., Gabriel, C., Mocaer, E., Mongeau, R., & Lanfumey, L. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.125 · Cited by 91
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84
Role of melatonin in mood disorders and the antidepressant effects of agomelatine
Srinivasan, V., De Berardis, D., Shillcutt, S. D., & Brzezinski, A. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.711314 · Cited by 84
Sakashita, Y., Abe, K., Katagiri, N., Kambe, T., Saitoh, T., Utsunomiya, I., Horiguchi, Y., & Taguchi, K. (2015) · Biological ^|^ Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00315 · Cited by 81
Agomelatine facilitates positive versus negative affective processing in healthy volunteer models
Harmer, C. J., de Bodinat, C., Dawson, G. R., Dourish, C. T., Waldenmaier, L., Adams, S., Cowen, P. J., & Goodwin, G. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376689 · Cited by 77
Finnema, S. J., Stepanov, V., Ettrup, A., Nakao, R., Amini, N., Svedberg, M., Lehmann, C., Hansen, M., Knudsen, G. M., & Halldin, C. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.08.035 · Cited by 72
Fornaro, M., McCarthy, M. J., De Berardis, D., Pasquale, D., Martino, Colicchio, Cattaneo, D'Angelo, Fornaro, P., & Tabaton (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41557 · Cited by 67
A single dose of mirtazapine modulates neural responses to emotional faces in healthy people
Rawlings, N. B., Norbury, R., Cowen, P. J., & Harmer, C. J. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1983-8 · Cited by 65
Tuma, J., Strubbe, J. H., Mocaër, E., & Koolhaas, J. M. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.02.004 · Cited by 60
Role for the Clock Gene in Bipolar Disorder
McClung, C. A. (2007) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2007.72.031 · Cited by 57
Cardiovascular adverse effects of newer antidepressants
Mago, R., Tripathi, N., & Andrade, C. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908709 · Cited by 54
Ignácio, Z. M., Réus, G. Z., Abelaira, H. M., Maciel, A. L., de Moura, A. B., Matos, D., Demo, J. P., da Silva, J. B. I., Gava, F. F., Valvassori, S. S., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.044 · Cited by 53
Delayed sleep-wake phase disorder and its related sleep behaviors in the young generation.
Futenma, K., Takaesu, Y., Komada, Y., Shimura, A., Okajima, I., Matsui, K., Tanioka, K., & Inoue, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1174719 · Cited by 42
Chronotherapeutics (light and wake therapy) as a class of interventions for affective disorders
(2012) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52002-9.00042-5 · Cited by 42
Koresh, O., Kozlovsky, N., Kaplan, Z., Zohar, J., Matar, M. A., & Cohen, H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.012 · Cited by 40
Pringle, A., McCabe, C., Cowen, P., & Harmer, C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112474523 · Cited by 37
Dagyte, G., Luiten, P. G., De Jager, T., Gabriel, C., Mocaër, E., Den Boer, J. A., & Van der Zee, E. A. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22697 · Cited by 32
“, 2003) and serotonergic receptor (5-HT2C) antagonist (Millan et al., 2003).”
BackgroundInfluentialProfile of agomelatine and its potential in the treatment of generalized anxiety disorder
Levitan, M., Papelbaum, M., & E Nardi, A. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s67470 · Cited by 25
Metadata
- Authors
- Millan, M. J., Gobert, A., Lejeune, F., Dekeyne, A., Newman-Tancredi, A., Pasteau, V., Rivet, J.-M., & Cussac, D.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 306
- Issue
- 3
- Pages
- 954-964
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2103431948
- Cited by
- 516
- References
- 47
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.